Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 14 of 14 publications.

Mladsi D, Zhou X, Mader G, Sanon M, Wang J, Barnett C, Willey C, Seliger S. Mortality risk in patients with autosomal dominant polycystic kidney disease. BMC Nephrol. 2024 Feb 16;25(1):56. doi: 10.1186/s12882-024-03484-3

Danese D, Goss D, Romano (DeMuro) C, Gupta C. Qualitative assessment of the patient experience of primary hyperoxaluria type 1: an observational study. BMC Nephrol. 2023 Oct 26;24(1):319. doi: 10.1186/s12882-023-03365-1

Mader G, Mladsi D, Sanon M, Purser M, Barnett CL, Oberdhan D, Watnick T, Seliger S. A disease progression model estimating the benefit of tolvaptan on time to end-stage renal disease for patients with rapidly progressing autosomal dominant polycystic kidney disease. BMC Nephrol. 2022 Oct 18;23(1):334. doi: 10.1186/s12882-022-02956-8

Walley D, Twiss J, Doward L, Balp MM, Brass C, Loeffler J, Lopez P, Cai J, Cryer D, Anstee Q, Sanyal A. Patient-reported symptoms and impact in nonalcoholic steatohepatitis: an evaluation of the NASH-CHECK, a novel PROM in NASH. Poster presented at the EASL: The Digital International Liver Congress; August 27, 2020. Digital. [abstract] J Hepatol. 2020 Jan; 73:S422-3. doi: 10.1016/S0168-8278(20)33053-1

Breckons M, Doward L, McSweeney L, Balp MM, Twiss J, Oluboyede Y, Vale L, Ternent L, Brass C, Sanyal A, Anstee Q. Evaluating the patient-perceived impact of non-alcoholic steatohepatitis with compensated cirrhosis. Poster presented at the EASL: The Digital International Liver Congress; August 27, 2020. digital. [abstract] J Hepatol. 2020 Jan; 73:S423. doi: 10.1016/S0168-8278(20)33053-1

Doward L, Balp MM, Twiss J, Slota C, Cryer D, Langford A, Collen R, Agashivala N, Brass C, Anstee QM, Sanyal A. Measuring what matters to patients: the development of the NASH-CHECK, a new patient-reported outcome instrument for nonalcoholic steatohepatitis. Poster presented at the 2018 EASL International Liver Conference; April 13, 2018. Paris, France. [abstract] J Hepatol. 2018 Apr; 68(Suppl 1):S570.

Doward LC, Balp MM, Stewart KE, Cryer D, Langford A, Twiss J, Agashivala N, Brass C, Anstee QM, Sanyal A. Exploring the patient perceived impact of non-alcoholic steatohepatitis. Poster presented at the 2017 EASL International Liver Conference; April 2017. Amsterdam, The Netherlands. [abstract] J Hepatol. 2017 Apr; 66(1 Supplement):S422-3. doi: 10.1016/S0168-8278(17)31208-4

Willis TA, Hartley S, Glidewell L, Farrin AJ, Lawton R, McEachan RRC, Ingleson E, Heudtlass P, Collinson M, Clamp S, Hunter C, Ward V, Hulme C, Meads D, Bregantini D, Carder P, Foy R. Action to support practices implement research evidence (ASPIRE): protocol for a cluster-randomised evaluation of adaptable implementation packages targeting 'high impact' clinical practice recommendations in general practice. Implement Sci. 2016 Feb 29;11(25). doi: 10.1186/s13012-016-0387-5

Tami-Maury I, Vidrine DJ, Fletcher FE, Danysh H, Arduino R, Gritz ER. Poly-tobacco use among HIV-positive smokers: implications for smoking cessation efforts. Nicotine Tob Res. 2013 Dec;15(12):2100-6. doi: 10.1093/ntr/ntt107.

Sunyer J, Forastiere F, Pekkanen J, Plana E, Kolz M, Pistelli R. Interaction between smoking and the interleukin-6 gene affects systemic levels of inflammatory biomarkers. Nicotine Tob Res. 2009 Nov;11(11):1347-53.

Monchuk DC, Rousu MC, Shogren JF, Nonnemaker J, Kosa KM. Decomposing the value of cigarettes using experimental auctions. Nicotine Tob Res. 2007 Jan;9(1):93-9.

David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, Day A, Stumpff J, Hutchison K, Murphy M, Johnstone E, Griffiths SE, Walton RT. Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res. 2003 Dec 1;5(6):935-42.

Niaura R, Britt DM, Borrelli B, Shadel WG, Abrams DB, Goldstein MG. History and symptoms of depression among smokers during a self-initiated quit attempt. Nicotine Tob Res. 1999 Sep 1;1(3):251-7.

Calvet X, Navarro M, Gil M, Mas P, Rivero E, Sanfeliu I. Seroprevalence and epidemiology of Helicobacter pylori infection in patients with cirrhosis. J Hepatol. 1997 Jun;26(6):1249-54.